Patent Insights on Yeast Biomass and Oleogel Market Prospects

Teaser: Yeast to reduce plant off-notes, structured oils to replace solid fats: two new European patent publications address practical development challenges. Commercial prospects depend on different conditions. For yeast, the focus is transferring an ingredient already on offer to specific applications; for phytosterol oleogels, permitted uses determine the accessible market.

EP 4 812 035 A1 from Moa Biotech and EP 4 812 039 A1 from Kayama Foods were published in Europe on 30 September. Their underlying international applications were already public in 2025. The new event is their European publication. Both documents concern applications; no grant or national protection is established here.[1] For development and purchasing teams, the question is which applications are technically, legally and economically viable.

Yeast Biomass for Plant Proteins

Moa's application concerns mixing plant proteins with inactivated yeast biomass to reduce plant off-notes. Independent claims cover processes, use and a food obtained by the process. Further claims address extrusion and retention of meaty aroma compounds. Examples include soya and pea proteins and Kluyveromyces marxianus.[2]

In our assessment, commercial relevance is greatest for extruded meat alternatives and savoury protein products. Reducing unwanted notes could lower flavouring requirements and facilitate different protein sources. This potential needs testing against the yeast's own flavour, texture changes and dosage costs. A sensory improvement in one formulation requires application trials before transfer to another protein, extruder or product matrix.

MOA already offers “MOA YEAST” as a functional ingredient, naming applications including plant-based burgers, bakery products and snacks. The company describes it as “Non-Novel Food” in the EU and GRAS in the USA; its own technical communication specifies “self-affirmed GRAS”.[3] A public ingredient offering therefore exists. This research has not verified sales volumes or supply prices, or established that every patented embodiment matches the commercial product.

EU and US Target Markets and Evidence Requirements

EU commercialisation of yeast biomass is realistic in principle. The supplier's Non-Novel statement provides a useful starting point. Before use, its supporting evidence must match the supplied biomass: microorganism, process, composition and intended use need clear identification. The word “yeast” alone cannot establish that assessment.

Article 4 of the Novel Food Regulation requires food businesses to check status. Where uncertain, they should consult the Member State of intended first marketing. If the assessment establishes novel-food status, authorisation and inclusion in the Union list are required before marketing. Documented significant consumption before 15 May 1997 can support non-novel status.[4] The earlier Food Essentials article “Innovative Ingredient or Novel Food?” explains this initial decision; the additional issue here is linking the assessment to the specific patented material.

The USA is a plausible second market because MOA expressly claims GRAS status for intended uses. An independent GRAS determination is not FDA approval. Customers would need access to its scientific basis and covered conditions of use. FDA notification remains voluntary; the proposal published on 11 August 2026 would require notification for certain uses.[5] This possible change matters for project planning.

Our market assessment: the strongest initial opportunity is B2B reformulation in the EU and USA. Manufacturers can measure benefits in an existing product rather than first building a new consumer category. Sensory improvement, total formulation cost, consistent quality and reliable supply are decisive. Other international markets remain potential expansion targets; specific local clearances were not demonstrated. The off-note application does not establish an equally clear benefit for food supplements.

Phytosterol Oleogels and EU Market Access Constraints

Kayama's application describes a fat substitute combining oil with a three-dimensional scaffold containing phytosterol and ester. Claim 1 couples this structure with alternative criteria for oil binding, moisture or lipophilic content. An independent process claim describes heating, dissolution and cooling; further embodiments include gamma-oryzanol.[6]

We see technical potential in bakery products, plant-based alternatives and other foods requiring solid or semi-solid fats. Kayama promotes functional fats for existing formulations and production processes.[6] Lower saturated-fat content could be a development benefit; the actual improvement depends on the oil and finished food. The reviewed documents did not establish product-specific EU authorisation or widespread commercial introduction.

EU authorisations already exist for phytosterols and enriched oils. These cover defined specifications and food categories, including certain spreads, milk products, soya drinks and sauces. For added phytosterols, the Food Information to Consumers Regulation also requires labelling expressly targeting people seeking to lower cholesterol, alongside further consumption advice and warnings.[7] This limits positioning as a universal fat replacement for the general market.

An EU opportunity therefore starts with a permitted application and demonstrated specification compliance. The listed entries do not provide blanket coverage for meat alternatives or general bakery products. Gamma-oryzanol also cannot simply be equated with phytosterols esterified with food-grade fatty acids as specified in those entries. Depending on composition and process, a separate status assessment and potentially new authorisation or extension of uses would be required.[4][7] The structuring components must also be assessed as ingredients or additives; where applicable, the separate additive-authorisation route applies.[7] US use requires its own use-specific safety and legal basis.[5] The EU and USA are therefore potential targets, with oleogel market access more dependent on outstanding evidence.

European Revocation of the Krill Hydrolysate Patent

In T 1227/24 of 18 June 2026, the EPO Board of Appeal revoked Aker BioMarine's EP 3 749 339 B1. Grounds included unachievable low concentration ranges and lack of inventive step in remaining process requests.[8] This is a European competitive event for marine protein ingredient suppliers. Other family rights and non-European markets require separate assessment; no general freedom to operate is inferred.

For Food Essentials, yeast currently offers the more concrete starting point for application-led development. For oleogels, the permitted target application should be established before substantial formulation investment. We help bring ingredient identity, technical suitability and market access together into a robust project decision.

Note: editorial technology and market assessment, not a freedom-to-operate or definitive validity opinion. Complete EPO register files for the new publications were inaccessible.

Sources

Checked on 4 October 2026.

[1] EPO Bulletin 40/2026, pp. 24–25.
[2] WO 2025/242931 A1, claims and examples.
[3] MOA YEAST; MOA on US status.
[4] Regulation (EU) 2015/2283, Articles 3, 4, 6, 10; Commission on status consultation.
[5] FDA GRAS procedure; GRAS proposal, 11 August 2026.
[6] WO 2025/109601 A1, claims; Kayama product offering.
[7] Regulation (EU) 2017/2470, Annex on phytosterols and enriched oils; Regulation (EU) 1169/2011, Annex III.5; Regulation (EC) 1333/2008, Articles 3–4.
[8] EPO T 1227/24, 18 June 2026.

Note: This News item provides professional context and does not replace a legal, microbiological, chemical or product-specific assessment. Images: AI-generated